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Respiratory syncytial, 
parainfluenza and influenza virus 
infection in young children with 
acute lower respiratory infection in 
rural Gambia
Grant A. Mackenzie1,2,3,4*, Aminata Vilane1, Rasheed Salaudeen1, Lenny Hogerwerf5, 
Sharon van den Brink6, Lisa A. Wijsman6, pieter Overduin6, Thierry K. S. Janssens6, 
Thushan I. de Silva1,7, Marianne A. B. van der Sande5,8,9, Beate Kampmann1,10,11 & 
Adam Meijer6,11
Respiratory viral infections contribute significantly to morbidity and mortality worldwide, but 
representative data from sub-Saharan Africa are needed to inform vaccination strategies. We conducted 
population-based surveillance in rural Gambia using standardized criteria to identify and investigate 
children with acute lower respiratory infection (ALRI). Naso- and oropharyngeal swabs were collected. 
Each month from February through December 2015, specimens from 50 children aged 2–23 months 
were randomly selected to test for respiratory syncytial (RSV), parainfluenza (PIV) and influenza 
viruses. The expected number of viral-associated ALRI cases in the population was estimated using 
statistical simulation that accounted for the sampling design. RSV G and F proteins and influenza 
hemagglutinin genes were sequenced. 2385 children with ALRI were enrolled, 519 were randomly 
selected for viral testing. One or more viruses were detected in 303/519 children (58.4%). RSV-A was 
detected in 237 and RSV-B in seven. The expected incidence of ALRI associated with RSV, PIV or 
influenza was 140 cases (95% CI, 131–149) per 1000 person-years; RSV incidence was 112 cases (95% 
CI, 102–122) per 1000 person-years. Multiple strains of RSV and influenza circulated during the year. 
RSV circulated throughout most of the year and was associated with eight times the number of ALRI 
cases compared to PIV or IV. Gambian RSV viruses were closely related to viruses detected in other 
continents. An effective RSV vaccination strategy could have a major impact on the burden of ALRI in 
this setting.
The introduction of conjugate vaccines against Haemophilus influenzae type b and Streptococcus pneumoniae in 
many countries has contributed to reductions in pneumonia deaths over the last two decades1,2. The introduc-
tion of pneumococcal conjugate vaccine in The Gambia was associated with a 61% reduction in severe hypoxic 
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pneumonia3. However, the incidence of all-cause acute lower respiratory infection (ALRI) remains high3 with 
an estimated 921,000 deaths due to ALRI in children <5 years of age in 2015, 490 000 of which occurred in 
sub-Saharan Africa1.
In order to address the ongoing burden of virus-associated ALRI and to develop evidence-based vaccination 
strategies, additional data are needed from low-income settings. Recent case-control studies from low-income 
countries have established an etiologic association between ALRI and respiratory syncytial (RSV), parainfluenza 
(PIV), influenza (IV) and human metapneumo viruses4,5. However, these studies could not calculate disease inci-
dence. A recent systematic review estimated the global number of cases of RSV-associated ALRI in 2015 at 33.1 
million, 3.2 million hospital admissions and 59 600 deaths with 45% of cases occurring before 6 months of age6. 
Incidence varied by location, with only three (two unpublished) African studies reporting disease incidence7, 
with none in West Africa. Thus, additional African data are urgently needed as several RSV vaccine candidates are 
in development with consideration of maternal, neonatal and infant vaccination strategies8.
Here we present the incidence of ALRI associated with RSV, PIV or IV in young children in The Gambia, 
including the clinical features and temporal circulation. We also evaluate specimen collection and storage meth-
odologies and analyse antigenic sites that may impact on vaccination strategies.
Methods
Study setting. The Gambia is a small West African country with a population of approximately 2.1 million. 
The Basse Health and Demographic Surveillance Systems (BHDSS) in the rural east of the country had an esti-
mated population of 179 932 in 2015 with 12,318 aged 2–23 months. The Basse Health Centre is a primary and 
secondary care facility in Upper River Region of The Gambia, providing referral services to five peripheral health 
facilities in the BHDSS. HIV prevalence in antenatal attendees was 1.6% in 20149. Transmission of Plasmodium 
falciparum is associated with a rainy season from June until October. 7-valent pneumococcal conjugate vaccine 
(PCV7) was introduced in 2009 and replaced by PCV13 in 2011.
Study design and procedures. This study was nested within a population-based surveillance study 
for suspected pneumonia, septicemia and meningitis, designed to measure the impact of PCV introduction. 
Surveillance methodology10 and results3,11 have been previously published. Surveillance commenced in 2008 and 
included all BHDSS residents. We added the collection of nasopharyngeal (NP) and oropharyngeal (OP) swabs 
from all surveillance patients from February 2015 onwards with the aim to measure pneumococcal carriage. The 
study presented here used data and stored specimens collected between February 10 and December 31, 2015.
Surveillance nurses screened all outpatients and inpatients at all health facilities in the BHDSS, 24 hours a 
day, 7 days per week, using standardized criteria for referral to clinicians (Supplementary Table S1). Clinicians 
applied standardized criteria to make a surveillance diagnosis (Supplementary Table S2) and requested blood 
culture, chest radiography, NP and OP specimens according to a standardized protocol (Supplementary Table S3). 
Flocked nylon swabs (Copan, Murietta, CA, USA) were used to collect separate NP and OP specimens12.
Specimens were placed in skimmed-milk-tryptone-glucose-glycerol (STGG) and transported within one hour 
to the laboratory in Basse and stored at −70 °C.
We defined ALRI as cough or difficulty breathing for 14 days or less and one or more of the following: raised 
respiratory rate for age, lower chest wall indrawing, nasal flaring, grunting, oxygen saturation <92%, altered 
consciousness, prostration, seizures, dull chest percussion note, coarse crackles, or bronchial breathing. Children 
were eligible if aged 2–23 months, admitted to hospital, and excluded if the surveillance diagnosis was septicemia 
or meningitis alone without suspected pneumonia. Children with ALRI and proven invasive bacterial disease 
were included.
Specimen processing. Validation of STGG media for molecular viral diagnosis. To validate virus detection 
in STGG, we simulated clinical specimens using two different media, STGG or gelatin, lactalbumin hydrolysate, 
yeast extract in Hank’s medium (GLY) virus transport medium (gold standard) spiked with virus. First, serial 
10-fold dilutions of specimens containing IV A(H3N2), A(H1N1)pdm09, B-Victoria lineage, B-Yamagata line-
age, RSV-A and RSV-B were prepared in GLY. Duplicate specimens from each dilution were prepared by mixing 
2 μl of diluted specimen with 200 μl STGG or GLY. All specimens were also spiked with control equine arteritis 
virus (EAV). RNA was extracted manually (Total RNA kit, Roche). The duplicate specimens were subjected to 
real-time RT-PCR for IV, RSV and EAV.
In order to validate the molecular detection method in field samples, we first randomly selected approximately 
50 patients in both August and September 2015 who met our definition of ALRI. Stored aliquots of NP and OP 
specimens from these patients were used in validation experiments at the Centre for Infectious Diseases Research, 
Diagnostics and laboratory Surveillance at the National Institute for Public Health and the Environment (RIVM), 
the Netherlands.
Analysis of randomly selected field specimens. Following the demonstration of successful detection of viral 
nucleic acid and the validation and concordance of viral detection in NP and OP specimens, we went on to ran-
domly selected approximately 50 patients per month from February through July and October through December 
2015. Thus, the overall analysis included specimens from 11 months (February through December 2015).
Extraction of nucleic acid from the clinical specimens and control material in STGG was performed on a 
MagNA Pure 96 Instrument (Roche) using the MagNA Pure 96 DNA and Viral NA Small Volume Kit (Roche). 
Specimens and controls were spiked with EAV as an internal control. One-step real-time reverse transcription 
(RT)-PCR using TaqMan Fast Virus 1-step Master Mix (Applied Biosystems Life Technologies) was done for the 
detection and typing of IV, RSV, PIV and EAV. We determined IV subtyping and lineage using the same approach. 
The Primers and probes used and the PCR protocol are listed in Supplementary Table S4. For each RT-PCR 
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positive control (strains indicated in Supplementary Table S5), two negative controls consisting of STGG and 
GLY were included.
Sequencing of RSV and influenza virus. We sequenced the length of the G-protein gene encoding part of the 
transmembrane portion and the whole external part of the G-protein and part of the F-protein gene covering 
antigenic sites Ø, II and VIII from selected RSV positive specimens using protocols adapted from Agoti et al.13. 
and Xia et al.14. The full length hemagglutinin gene was sequenced from selected IV positive specimens. All 
primer sequences and protocols used can be found in Supplementary Tables S6–S9. Viruses were selected based 
on viral load [PCR Cycle threshold (Ct) value <30] and distribution across the months of specimen collection.
Analysis. We restricted the analysis of clinical characteristics to children resident in the BHDSS area. 
Categorical data were used to calculate proportions and comparisons used the χ2 or Fisher’s exact test. Mean 
values for continuous data were compared using t-tests. Tests of association were two-sided with statistical sig-
nificance set at p < 0.05.
The expected value and 95% confidence limits for the total number of cases among all children resident in 
the BHDSS and presenting with ALRI between 1 February and 31 December 2015 were derived by simulation 
taking into account the monthly sampling of patients resident in the study area (Supplementary Material p 19). 
We simulated the monthly proportions of children with viral-associated ALRI, assuming a binomial distribution 
with the observed proportion of positive samples from the number of patients sampled each month. We then 
randomly sampled from an independent binomial distribution with these proportions, from the whole popula-
tion of ALRI cases to estimate the number of positive cases each month at the population level. This was repeated 
1,000,000 times for each month and the expected number of positive cases and their 95% confidence limits were 
estimated as the mean and 2.5% and 97.5% percentiles of the simulated values. We used these expected values and 
the mid-point population (12,318 × [11/12]) to calculate the expected incidence of ALRI associated with each of 
the target viruses with 95% confidence limits. Simulations used R v3.43 software.
In order to study the viruses circulating in the region, isolates detected in children resident within and 
those resident outside the BHDSS were eligible for selection for genome sequencing. We used the sequences of 
Gambian RSV and IV from this study, selected sequences extracted from GenBank for RSV and GISAID for IV, 
and selected sequences of RSV and IV from Dutch surveillance for influenza-like illness and other acute res-
piratory infections to infer phylogenetic trees of the genetic relatedness of viral genes encoding the G-protein of 
RSV-A and RSV-B and the hemagglutinin gene of IV (Supplementary Methods p. 21–22, phylogenetic analysis 
and Supplementary Table 14). The RSV G-protein and IV hemagglutinin amino acid sequences were analysed 
for substitutions compared to parental strains for RSV or vaccine strains for IV. RSV F-protein gene sequences 
were analysed for antigenic site composition in the context of RSV-A strain A2 and RSV-B strain B1 that are fre-
quently used in vaccine development15. In addition, potential N-glycosylation sites were identified for RSV F- and 
G-proteins and IV hemagglutinin and potential O-glycosylation sites for RSV G-protein.
Ethical considerations. The Gambia Government/MRC Institutional Ethics Committee approved the study 
which was conducted in accordance with the relevant guidelines and regulations. Parents or guardians of all chil-
dren gave written informed consent.
Results
Participant enrolment and characteristics. During the observation period the surveillance system 
enrolled 2518 children aged 2–23 months, 2385 met criteria for ALRI and 532 specimens were randomly selected 
for viral testing (519 BHDSS residents).
Validation of STGG media for virus detection. Ct values for IV A and B controls generated from RNA 
extracted from STGG were consistently slightly higher (average 1.2 and 1.0 higher Ct respectively) than those 
generated from RNA extracted from the gold standard GLY, and similar was observed for RSV A and B controls 
(average 1.2 and 1.4 higher Ct respectively). The fraction positive for RSV and IV among the four replicates per 
dilution started to drop one 10-fold dilution step earlier with RNA extracted from STGG compared to GLY. Taken 
together these findings suggest a minor but clear inhibiting effect of STGG on RNA extraction and/or RT-PCR 
efficiency. We conclude that detection of IV and RSV in STGG is up to 10 times less sensitive than in GLY. Despite 
the reduced sensitivity of viral detection in STGG, the collection of clinical specimens in the acute phase of dis-
ease when viral load is high still provides good clinical performance for the detection of IV, RSV and PIV.
Virus detection in clinical specimens. STGG specimens were tested from a total of 532 patients (13 not 
resident in the BHDSS) with an average of 48 (range 42–58) per month from February through December 2015. 
One or more viruses were detected in 303/519 patients (58.3%) with 14 cases (5%) of co-infection (Fig. 1). RSV-A 
was detected in 237/519 (45.9%) patients, and constituted the predominant virus in the dry season months 
February through June as well as during the rainy season July through October (Fig. 1). RSV-B was uncommon, 
detected in only seven patients. PIV-1 was detected in only one patient, while PIV-3 was detected in 16 (one with 
RSV-A co-infection) mainly in the first half of the year and PIV-4 was detected in 16 (three as a co-infection with 
RSV-A) primarily in the second half of the year (Fig. 1). A small number of influenza A(H1N1)pdm09 cases 
(n = 5) were detected early in the year with A(H3N2) appearing later in the year (n = 15). B/Yamagata infections 
(n = 19) began when A(H1N1)pdm09 infections started to drop and peaked at the same time as A(H3N2) viruses 
in the rainy season months of September and October (Fig. 1). In general, OP swabs had higher Ct values than NP 
swabs indicative of a difference in viral load (Table 1). Detection of RSV was greater in NP versus OP specimens.
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Clinical features of patients. The demographic and clinical features of the selected patients with ALRI 
(n = 519) were similar to those who were not selected (n = 1866) [Supplementary Table S10]. Table 2 shows the 
clinical characteristics of the 519 children according to four categories of ALRI. Wheeze was more common 
among children with detectable virus compared to those without (p = 0.005). The prevalence of viral detection 
was higher in those aged 2–11 months (61.1%, 196/321) than 12–23 months (54.0%, 107/198), although the dif-
ference was not significant (p = 0.12). However, RSV was more commonly detected in those aged 2–11 months 
(51.4%, 165/321) than those aged 12–23 months (36.4%, 72/198) [p = 0.0008].
Incidence of acute lower respiratory infection. There were 303 cases of ALRI associated with at 
least one of the target viruses observed among the 519 selected resident patients (Table 3 and Supplementary 
Table S11). Simulation of the expected number of cases in all patients with ALRI during the observation period 
took into account the random monthly sampling and found an expected 1543 cases (Table 3 and Supplementary 
Tables S11–S13). The expected incidence of ALRI associated with RSV, PIV or IV was 140 cases per 1000 popu-
lation per year (Table 3); that is, we estimated that 14% of 2–23 month old children in the population presented 
with virus-associated ALRI in 2015. The incidence of RSV-A associated ALRI was 112 per 1000 population per 
year; we therefore estimated that 11% of the 2–23 month old population presented with ALRI associated with 
RSV-A. Incidence of viral-associated ALRI was substantially greater in the first compared to the second year of 
life (Table 3).
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Figure 1. Proportion (bars) and number of positive cases (numbers in bars) per pathogen per month. Cases 
positive for two viruses are shown as one case. Indicated are also the minimum (lowest 19 °C in January) and 
maximum (highest 43 °C in April and May) temperatures in °C and rainfall in mm (lowest 0 mm, highest 
275.5 mm in August) per month at weather station Tambacounda, Senegal, most close to Upper River Region, 
The Gambia (https://www.worldweatheronline.com/basse-weather-averages/upper-river/gm.aspx).
Pathogen; N
Concordant Discordant
n
NP +ve OP +ve NP +ve, OP −ve NP −ve, OP +ve
(Ct median; 
IQR)
(Ct median; 
IQR) n
(Ct median; 
IQR) n (Ct median; IQR)
RSV-A; 237* 206 (26.4; 24.2–28.8) (30.7; 28.5–33.2) 25 (32.2; 30.5–35.8) 6 (29.2; 24.7–32.7)
RSV-B; 7 5 (27.8; 26.8–29.4) (30.5; 30.4–32.9) 1 (33.2; na) 1 (40.0; na)
Influenza A; 19 17 (29.6; 26.6–31.2) (33.0; 30.1–33.7) 1 (32.8; na) 1 (33.1; na)
Influenza B; 20 17 (27.4; 23.4–30.8) (30.9; 28.5–32.6) 1 (36.1; na) 2 (33.0; na)
PIV-1; 1 0 1 (31.9; na) 0
PIV-3; 16 6 (28.2; 26.8–28.5) (36.1; 32.2–37.6) 10 (27.6; 25.3–29.6) 0
PIV-4; 16 9 (30.3; 29.9–31.7) (32.6; 31.8–36.0) 6 (31.4; 30.5–33.0) 1 (37.9; na)
Table 1. Concordance of results between nasopharyngeal (NP) and oropharyngeal (OP) specimens. *One 
patient positive for RSV-A not included in this analysis because no oropharyngeal swab was available. Ct = real-
time RT-PCR cycle threshold value; IQR = interquartile range; +ve = positive; −ve = negative; na = not 
applicable.
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Viral genetic sequencing. Phylogenetic trees using the RSV G-protein gene and the IV hemaggluti-
nin gene sequencing from 19 RSV and 16 IV strains selected throughout the study period, are found in Fig. 2 
and Supplementary Figs S1–S5. All Gambian RSV-A viruses clustered in the ON1 clade and all but one of the 
sequenced RSV-A viruses clustered with 2014 and 2015 viruses from The Netherlands and the USA in a subgroup 
of clade ON1 characterised by specific amino acid substitutions. Further diversification was seen characterised 
by particular common amino acid substitutions. One Gambian RSV-A clustered with 2015 and 2016 viruses 
from New Zealand and The Netherlands in another subgroup of clade ON1 characterised by specific amino acid 
substitutions. All five sequenced RSV-B clustered in a subgroup of clade BA characterised by specific amino acid 
substitutions with 2013–2016 RSV-B viruses from other continents. One Gambian RSV-B virus lost two stop 
codons resulting in a longer G-protein. Several of the amino acid substitutions of the clusters containing the 
Gambian RSV-A or RSV-B resulted in the gain or loss of potential O-glycosylation sites in the G-protein. Less 
complete G-protein gene sequences from Kenya in 2014–2015 did not cluster with Gambian RSV-A sequences 
(Supplementary Fig. S1). For RSV-B, a small proportion of 2015 and all 2016 Kenyan RSV-B, clustered with 
Gambian RSV-B in a larger subgroup of clade BA (Supplementary Fig. S1). Full details of the G-protein sequence 
analysis can be found in the Supplementary Material p. 31. Gambian RSV F-protein sequences showed that key 
antigenic sites were highly conserved, although some amino acid differences were observed between RSV-A and 
RSV-B (Supplementary Fig. S6). RSV-B had one N-glycosylation site less than RSV-A at amino acid 126 due to 
T128L difference. Circulating IV genotypes were similar to the rest of Africa and The Netherlands in 2015, with 
similar amino acid changes compared to the recommended vaccine strains (Supplementary Material p. 32).
Discussion
Our analyses from population-based surveillance in 2015 in rural Gambia provide reliable data on the incidence 
of ALRI associated with RSV, PIV and IV, its clinical characteristics and a detailed description of the circulation 
of RSV, PIV and IV throughout the year with genotypic descriptions of the prevalent RSV and IV. RSV-A was the 
dominant virus detected with a very high incidence of associated ALRI.
Unlike the seasonal circulation of RSV that is generally observed in temperate16–18 and tropical climates19–21, 
RSV-A circulated almost throughout the year, similar to observations made in Senegal in 2012 and 2013 but not 
201422. PIVs, and IVs in particular, circulated for shorter periods of time. The predominance of one particular 
RSV type in one season, namely RSV-A in 2015, was similar to that observed in Mali (RSV-B in 2013)23, Senegal 
(RSV-B in 2012, RSV-A in 2013, RSV-B in 2014)22, Ghana (RSV-B in 2006 and 2013, RSV-A in 2014)21, and the 
United States (RSV- in 2015)16.
We used a monthly sampling design to estimate the expected number of cases during the observation period 
and estimated that 14% of children aged 2–23 months in the population presented with ALRI associated with 
RSV, PIV or IV and that 11% presented with ALRI associated with RSV-A. The incidence of any target virus and 
RSV-A associated ALRI within this demographically well-defined population was 140 and 112 cases per 1000 
population per year respectively. The three target viruses were highly prevalent, one or more being detected in 
58% of children with ALRI and RSV-A detected in 46% of children. The number of ALRI cases associated with IV 
and PIV respectively, was only 14% and 13% of the number associated with RSV.
Our finding of 46% prevalence of RSV-A in children with ALRI is higher than in most other studies, sug-
gesting that we observed a particularly intense RSV epidemic in 2015. In coastal Kenya the prevalence of RSV in 
children aged <5 years hospitalized with pneumonia from 2002–2007 was 15% (20% among infants) and 27% 
during epidemics (32% among infants)7. RSV prevalence was 36% in active case detection of clinical pneumonia 
in children aged <2 years in Mirzapur, Bangladesh in 1993–199624. During the conduct of the PERCH study of 
the etiology of childhood pneumonia in 2012/13 in Basse, the prevalence of RSV in children hospitalized with 
ALRI was 19.7%25.
The estimated incidence of RSV-A associated ALRI in our study is particularly high. We estimated an inci-
dence of 112 cases per 1000 population per year (168 per 1000 population per year <1 year of age) while other 
No virus detected & no 
radiologic pneumonia or 
bacteremia
(N = 185)
≥1 virus detected & no 
radiologic pneumonia or 
bacteremia
(N = 274)
Radiologic consolidation 
with or without viral 
detection
(N = 52)
All selected for 
viral testing
(N = 519)
Age 2–11 months 109 (58.9%) 180 (65.6%) 27 (52%) 321 (61.9%)
Age 12–23 months 76 (41.1%) 94 (34.3%) 25 (48%) 198 (38.2%)
Mean age in months (SD) 11.3 (5.9) 10.3 (6.3) 11.8 (6.5) 10.8 (6.2)
Female 82 (44.3%) 123 (44.9%) 29 (56%) 236 (45.5%)
Mean respiratory rate per minute (SD) 53 (10) 56 (10) 59 (14) 55 (11)
Wheeze 42 (22.7%) 96 (35.0%) 9 (17%) 150 (28.9%)
Lower chest wall indrawing 74 (40%) 159 (58.0%) 29 (56%) 264 (50.9%)
Mean O2 saturation (SD) 97.4 (7.0) 96.7 (3.2) 94.5 (5.9) 96.8 (5.2)
Treated as inpatient 84 (45.4%) 159 (58.0%) 42 (81%) 291 (56.1%)
Inpatient death 1 (<0.1%) 0 (0.0%) 1 (2%) 3 (0.6%)
Table 2. Clinical characteristics of a representative sample of 519 children aged 2–23 months with different 
categories of acute lower respiratory infection in 2015 and tested for RSV, PIV and IV, in rural Gambia. Note: 
Eight patients had bacteremia and no virus detected. SD, standard deviation.
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African studies using passive case detection have reported incidences of 117 and 3026 per 1000 person-years in 
children <1 year of age. Even in studies using active case detection the incidence of RSV disease has generally 
been similar to our study which used passive case detection. Reanalysis of active case detection data from a 
number of locations for a systematic review of RSV-associated ALRI found incidence in the first year of life of 38 
in India, 88 in Indonesia, 105 in Kenya, 149 in Bangladesh, 148 in Guatemala, 116 in Nigeria and 331 in South 
Africa6. Our estimated incidence of RSV disease in the first year of life was greater than in all these studies, which 
had used active case detection, apart from the South African study, indicating a very high burden in our setting. 
A recent study from Mali using active surveillance in infants less than 6 months of age reported a very high 
incidence of RSV detection at 537 per 1000 person-years23. We estimated that in a 12 month period, 16.8% of all 
infants in the population presented to health facilities with RSV-associated ALRI.
Similar to previous evaluations of the use of swabs collected in STGG for the detection of respiratory viruses, 
we showed that this is feasible27,28, which is important for other investigators wishing to generate results from 
specimens stored in STGG. However, we also found some loss of sensitivity compared to the gold standard virus 
transport medium. As the children were sampled at the acute phase of disease when virus shedding is high, this 
was however not a significant problem for our study. Our data confirm that collection of both OP and NP speci-
mens is associated with greater sensitivity29,30. Use of NP swabs alone would result in slight under-reporting of all 
pathogens. We found greater detection of RSV in NP compared to OP specimens (Table 1), whereas others have 
described comparable detection in OP and NP specimens29,30.
Phylogenetic sequence analysis of RSV-A and RSV-B G-protein genes showed that the Gambian viruses 
belonged to the recent globally spread clades ON1 and BA respectively and clustered with viruses from other 
continents, similar to the analysis of Kenyan RSV isolates, and suggesting intra- and inter-continental circula-
tion of RSV strains31–34. Separate analysis using less complete Kenyan G-protein gene sequences indicated no 
strong link between RSV-A viruses circulating in West and East Africa in 2015 (Supplementary Fig. S1). Only 
for Gambian RSV-B did we notice some association with Kenyan RSV-B from 2015 and 2016 (Supplementary 
Fig. S1). The subgroups of ON1 and BA to which the Gambian RSV belonged had specific patterns of gain and 
loss of potential O-glycosylation sites that might affect antigenicity and therefore allow repeat infection35,36. Many 
Age 2–11 mo
Observed number 
of cases
Expected number of 
cases (95% CI)
Expected incidence per 1000 
population per year (95% CI)
Any virus 196 991 (913, 1066) 197 (181, 212)
RSV-A 165 847 (765, 927) 168 (152, 184)
RSV-B 3 14 (0, 35) 3 (0, 7)
Influenza-A 9 51 (21, 85) 10 (4, 17)
Influenza-B 6 31 (8, 59) 6 (2, 12)
PIV-1 1 6 (0, 20) 1 (0, 4)
PIV-3 10 47 (19, 81) 9 (4, 16)
PIV-4 10 35 (12, 62) 7 (2, 12)
Age 12–23 mo
Any virus 107 561 (494, 626) 90 (79, 100)
RSV-A 72 389 (321, 457) 62 (51, 73)
RSV-B 4 22 (3, 47) 4 (0.5, 8)
Influenza-A 10 54 (23, 91) 9 (4, 15)
Influenza-B 14 74 (37, 115) 12 (6, 18)
PIV-1 0
PIV-3 6 28 (7, 55) 4 (1, 9)
PIV-4 6 33 (8, 64) 5 (1, 10)
Age 2–23 mo
Any virus 303 1543 (1439, 1644) 140 (131, 149)
RSV-A 237 1232 (1124, 1339) 112 (102, 122)
RSV-B 7 34 (10, 65) 3 (1, 6)
Influenza-A 19 97 (55, 144) 9 (5, 13)
Influenza-B 20 104 (60, 154) 9 (5, 14)
PIV-1 1 5 (0, 18) 0.5 (0, 2)
PIV-3 16 77 (40, 120) 7 (4, 11)
PIV-4 16 67 (33, 107) 6 (3, 10)
Table 3. Incidence of virus-associated acute lower respiratory infections in children aged 2–23 months from 
February to December 2015 in the Basse HDSS, rural Gambia; (mid-point population at risk: 2–11 mo = 5038, 
12–23 mo = 6254). Note: Values for the expected and 95% confidence limits for the number of cases in the 
population took into account the monthly sampling scheme, being generated by simulation using the number 
of observed cases each month, the number of patients tested each month and the proportion of all patients 
tested each month (see Methods and Supplementary Tables 11–13 and Supplementary Material p 19). Expected 
numbers of cases by simulation in age strata may not sum to the expected number of cases overall.
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RSV vaccines under development target site Ø of the pre-fusion form of the F-protein37. Recently, a new potent 
neutralizing antigenic epitope VIII has been identified in the pre-fusion protein F38. Similar to previous findings, 
site Ø and site VIII of Gambian RSV viruses were conserved among RSV-A and RSV-B but of different compo-
sition between both types39, an aspect relevant to the development of vaccines targeting pre-fusion F-protein. 
As site Ø of Gambian RSV has the wildtype profile, vaccines under development are expected to accurately 
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Figure 2. Phylogenetic tree for RSV-A, based on partial sequences of the G-protein gene. Protein sequence 
ranges from amino acid position 54 up to stop codon. +N and −N indicate gain and loss of N-glycosylation 
sites and +O and −O indicate gain and loss of O-glycosylation sites. Country codes in the virus names: 
ITA = Italy; JOR = Jordan; Kilifi = Kenya; MEX = Mexico; NZL = New Zealand; PER = Peru; US or 
USA = United States of America.
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target Gambian RSV. Nevertheless, observed differences in the G-protein and F-protein nucleotides and amino 
acids (Supplementary Material p. 31) indicate that prospective monitoring of F-protein antigenic sites would be 
required to monitor for the emergence of escape variants following the introduction of RSV immunization in The 
Gambia.
Currently, no influenza vaccines are used in The Gambia. Given the IV profiles and circulation dynamics, 
similar to those seen in Senegal (www.who.int/flunet) where an early and late peak in the same year are generally 
observed every second year, early use of the previous year Northern Hemisphere (NH) recommended vaccine 
composition and a switch to that for the Southern Hemisphere (SH) for vaccination later in the season could be 
considered. However, it may be that recommendations for the SH vaccine would be too late for a vaccination cam-
paign in late January/early February to cover the potential March-April circulation of IV. Our results showed that 
the global recommendations for the A(H1N1)pdm09 vaccine strain were appropriate for The Gambia but there 
was a mismatch for A(H3N2). NH recommendations for B/Yamagata were mismatched and the recommended 
SH vaccine was appropriate (see Supplementary Material p. 32).
Our study had a number of limitations. Due to the inability to detect all cases in the population our estimates 
of incidence are minimal estimates of the true incidence. The observation period of 11 months was not able to 
capture the known year-to-year variability in the prevalence and seasonality of different respiratory viruses. We 
excluded those aged <2 months, and although the peak age for RSV disease is between 3–11 months6, infants less 
than 2 months of age are at risk of severe disease. We tested for the three respiratory viruses expected to be most 
prevalent and did not include viruses such as human metapneumovirus. Inclusion of a larger number of viruses 
could have closed part of the diagnostic gap, especially for the months of November and December. The testing 
of only 22% of children with ALRI for viruses was largely overcome by a scheme of random monthly sampling 
and simulation of the expected number of unobserved cases. This approach provided a valid point estimate of 
incidence but wider confidence intervals. The ability to detect RSV and IV from swabs stored in STGG compared 
to the gold standard virus transport media can be generalised to PIV as all are enveloped viruses.
In conclusion, the very high incidence of RSV among young children with ALRI confirms the significant bur-
den of RSV disease, being eight times that of IV or PIV, and the potential for RSV transmission causing disease 
for up to 9 months of the year. Ongoing surveillance will improve our understanding of seasonal variation and the 
clinical impact of viral-associated ALRI. Furthermore, we have demonstrated that surveillance for viral pathogens 
is possible using STGG media, and so may easily be combined with studies of bacterial colonization. With several 
RSV vaccines in the late stages of development, our insights into intra- and inter-continental transmission of RSV, 
continental and local genetic variability and evolution, transmission and disease burden, will be critical to the 
design of vaccines and their evaluation in the future. Similarly, local baseline data are important to support delib-
erations about future national vaccine introductions. The novel methods and data generated by our integrated 
clinical, epidemiological and microbiological surveillance can guide the introduction of suitable RSV vaccines, by 
providing an essential baseline to assess their potential impact and guide future vaccination strategies, including 
the vaccination of women in pregnancy.
Data availability
The data generated during this study are available from the corresponding author on reasonable request and with 
approval from the Gambia Government/MRC Joint Ethics Committee.
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